Actinogen Medical’s lead asset, Xanamem, is a once-daily oral selective 11beta-HSD1 inhibitor, designed to cross the blood brain barrier and target excess brain cortisol, which has been associated with CI. The company is targeting two CI indications: for patients with mild CI in the early stages of Alzheimer’s disease (AD), and for patients with major depressive disorder. Positive clinical results in healthy adults demonstrated the drug’s initial efficacy, and a recent analysis of biomarker-positive patients using newly available plasma samples from the previous XanADu study in mild AD also showed clinical activity. Having received the requisite FDA authorisations, Actinogen plans to start its Phase IIb XanaMIA trial in patients with biomarker-confirmed early AD in H2 CY23. It started the XanaCIDD proof-of-concept Phase II trial in major depressive disorder in Q4 CY22 and plans to report top-line data in H1 CY24.